|
US6767897B2
|
|
Therapeutic uses of tri-, tetra-, penta-, and polypeptides
|
|
US6093797A
|
|
Tri-, Tetra-, Penta-, and polypeptides and their therapeutic use as an antidepressant agent
|
|
WO9731628A1
|
|
Peptidomimetics for the treatment of hiv infection
|
|
WO9710836A1
|
|
Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
|
|
US5910478A
|
|
Peptidomimetics inhibiting the oncogenic action of p21 ras
|
|
CN1187773A
|
|
Method for treatment of pain
|
|
WO9626716A1
|
|
Elcatonin controlled release microsphere formulation for treatment of osteoporosis
|
|
TW509574B
|
|
Tri tetra penta and polypeptides and their therapeutic use as an antidepressant agent
|
|
US5840683A
|
|
Peptides inhibiting the oncogenic action of p21 ras
|
|
US5767083A
|
|
Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
|
|
US5721207A
|
|
Method for treatment of pain
|
|
US5589460A
|
|
Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
|
